MRX-2843

DRUG2 trials

Sponsors

Meryx, Inc.

Conditions

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced CancerMetastatic CancerMixed Phenotype Acute LeukemiaNeoplasm MetastasisNeoplasmsNeoplastic Processes

Phase 1

Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors

CompletedNCT03510104

Meryx, Inc.Advanced Cancer, Metastatic Cancer, Neoplasm Metastasis +3

Start: 2018-05-22End: 2025-12-31Updated: 2026-01-08

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

RecruitingNCT04872478

Meryx, Inc.Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia

Start: 2022-04-01End: 2026-09-30Target: 50Updated: 2026-01-08

Related Papers

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

Cancers2022-12-1312 citations

Therapeutic Targeting of Mertk and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia

Blood2021-11-059 citations